Alpha Cognition Inc. (ACOGF)

0.4000 -0.0200 (-4.76%) At close: 12:28PM EDT

Alpha Cognition Inc.

750 West Pender Street
Suite 1200
Vancouver, BC V6C 2T8
Canada
604-564-9244
https://www.alphacognition.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Michael E. McFadden	CEO & Director	655.19k	N/A	1967
Mr. Kenneth Anthony Cawkell B.A., LL.B.	Founder, Consultant, Corporate Secretary & Director	97.23k	N/A	1951
Mr. Donald A. Kalkofen B.A.	Chief Financial Officer	546.1k	100.44k	1964
Ms. Lauren D'Angelo M.B.A.	Chief Operating Officer	530.21k	N/A	1978
Dr. Denis G. Kay Ph.D.	Chief Scientific Officer	180k	N/A	1957

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alpha Cognition Inc., a clinical stage biopharmaceutical company, develops treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

Corporate Governance

Alpha Cognition Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.